Patents Represented by Attorney Paul C. Steinhardt
-
Patent number: 5447838Abstract: The present invention has multiple aspects that include an intermediate composition (i.e., a marked stock calibrator solution) for preparing diluted calibrator solutions that are marked in proportion to the amount of calibrator contained therein; a diluted (i.e., working) calibrator solution made therefrom, a series of diluted calibrator solutions that are visually colored in proportion to the concentration of calibrator therein; a method for performing a diagnostic assay that employs a series of marked calibrator solutions; a method for confirming that a stock solution of calibrator has been diluted correctly; and a method for indirectly confirming the concentration of calibrator in a working calibrator solution.Type: GrantFiled: August 5, 1992Date of Patent: September 5, 1995Assignee: Hybritech IncorporatedInventors: Bruce Meiklejohn, Michael Chiapetta
-
Patent number: 5395754Abstract: The present invention is directed to a membrane-based immunoassay method for an analyte of interest having at least two sterically separate antigenic sites. The method comprises providing a reactive membrane having a calibration zone and a test zone, wherein the calibration zone is characterized by having a predetermined amount of the analyte of interest immobilized via a first antibody as a first specific binding pair to a solid phase, the immobilized first binding pair being covalently cross-linked such that any remaining binding sites on said first immobilized antibody are substantially incapable of further specifically binding to any additional analyte, but at least some of said analyte is capable of specifically binding to a preselected amount of a labelled second antibody.Type: GrantFiled: July 31, 1992Date of Patent: March 7, 1995Assignee: Hybritech IncorporatedInventors: Paul P. Lambotte, Robert C. Darter, Mark J. Sarno
-
Patent number: 5273743Abstract: The present invention has multiple aspects. In its first aspect the present invention is directed to a trifunctional antibody-like compound that has tissue, organ, cell or molecule specificity and which is capable of being bifunctional when immobilized, via binding, at the tissue, organ, cell or molecule for which it has specificity. In particular, the present invention is directed to a trifunctional antibody-like compound of Formula I:F.sub.1 ab'--L--F.sub.2 ab'--L--F.sub.3 ab' (1)wherein L is the same or two different moieties for cross-linking F.sub.1 ab', F.sub.2 ab' and F.sub.3 ab';wherein F.sub.1 ab' is an Fab'-like fragment of a polyclonal or monoclonal antibody having specificity for an antigen expressed by the organ, tissue, cell or molecule of interest;wherein F.sub.2 ab' is an Fab'-like fragment of a polyclonal or monoclonal antibody having the same specificity as F.sub.Type: GrantFiled: December 13, 1991Date of Patent: December 28, 1993Assignee: Hybritech IncorporatedInventors: Clarence Ahlem, Ann E. Huang
-
Patent number: 5262524Abstract: The present invention is directed to a method for extending the length of one of the three linker arms of the compound of Formula I in the production of novel trifunctional antibody-like compounds. Formula I is defined as follows: ##STR1## wherein X is ##STR2## wherein k=1 or 0; wherein Z is ##STR3## wherein s=1 or 0; wherein n=1 or 0;wherein q=1 or 0;wherein Y is ##STR4## wherein Y' is ##STR5## wherein p or m may be the same or different and are integers ranging from 0 to 20 with the provisos that when n=0, the sum of m and p is an integer ranging from 1 to 20, whereas when n=1, p and m are each an integer that is at least 1 and the sum of p and m is an integer ranging from 2 to 20;wherein R.sup.1 is straight or branched chain lower alkyl having from 1 to 6 carbon atoms or lower alkoxy having from 1-6 carbon atoms; andwherein R.sup.Type: GrantFiled: November 15, 1991Date of Patent: November 16, 1993Assignee: Hybritech IncorporatedInventors: Leslie D. Anderson, Clarence N. Ahlem, Ann E. Huang
-
Patent number: 5250297Abstract: A novel tumor-associated antigen expressed by lung adenocarcinoma is disclosed. The antigen, characterized by monoclonal antibody LA20207, has a molecular weight in the range of about 50,000 to about 80,000 daltons and an isoelectric point in the range of about 4.9 to about 6.5. Antibodies directed against the antigen, methods for their production and diagnostic and therapeutic uses therefor are also provided.Type: GrantFiled: August 31, 1992Date of Patent: October 5, 1993Assignee: Hybritech IncorporatedInventors: Lana S. Grauer, Julia P. Leung, Barry S. Wilson
-
Patent number: 5143210Abstract: The present invention is directed to a foldable carton for conveniently displaying the chemical reagents and for conveniently dispensing the chemically impregnated devices for use in performing diagnostic tests and provided in a diagnostic test kit format. The foldable carton of the present invention has two openings. The first opening, the cover panel, has a rack capable of containing thereon, from 1-4 containers of chemical reagents. Because the cover panel is secured to the front of the carton, when the cover panel is fully opened, so as to overlay the front wall of the carton, the chemical reagents contained thereon are forwardly displayed. Preferably, the inside face of the cover panel also contains an instruction panel for refreshing the recollection of those already familiar with the test procedure. The lower end of the front wall is provided with a dispensing flap that opens to permit the sequential withdrawal of a chemically impregnated test device that is slideably stacked within the carton.Type: GrantFiled: January 31, 1991Date of Patent: September 1, 1992Inventors: S. John Warwick, Lonna J. Williams, Robert F. Eisele
-
Patent number: 5120504Abstract: Disclosed herein is an improved apparatus for conducting immunoassays. The apparatus comprises a container, and a test zone to which is bound an antibody, typically a monoclonal antibody, or which is capable of extracting cells from a fluid sample. The test zone may be a membrane, filter or a porous matrix in which microspheres to which are bound antibody are entrapped. The apparatus further comprises a liquid absorbing zone which is composed of absorbent material which acts when in contact with the test zone to induce flow through the test zone when a fluid sample is added to it. At least one port in communication with the liquid absorbing zone and the opening of the container is provided to allow gas displaced by the addition of fluid to be discharged from the container. The flow of the displaced gas being in a direction opposite to the flow of assay reagents through the liquid absorbing zone.Type: GrantFiled: July 12, 1989Date of Patent: June 9, 1992Assignee: Hybritech IncorporatedInventors: Virginia Petro-Roy, Kim D. Blickenstaff
-
Patent number: 5091542Abstract: The present invention is directed to a compound for use as an intermediate in the production of novel trifunctional antibody-like compounds. More particularly, the present invention is directed to a compound of the formula: ##STR1## wherein X is ##STR2## wherein k=1 or 0;wherein Z is ##STR3## wherein s=1 or 0;wherein n=1 or 0;wherein q=1 or 0;wherein Y is ##STR4## wherein Y', is ##STR5## wherein p or m may be the same or different and are integers ranging from 0 to 20 with the proviso that when n=0, the sum of m and p is an integer ranging from 1 to 20, whereas when n=1, p and m are each an integer that is at least 1 and the sum of p and m is an integer ranging from 2 to 20;wherein R.sup.1 is straight or branched chain lower alkyl having from 1 to 6 carbon atoms or lower alkoxy having from 1-6 carbon atoms; andwherein R.sup.2 is hydrogen, phenyl, --COOH, or straight or branched chain lower alkyl having from 1-6 carbon atoms, with the proviso that the lower alkyl moiety may be mono substituted by --NH.sub.Type: GrantFiled: March 9, 1990Date of Patent: February 25, 1992Assignee: Hybritech IncorporatedInventors: Clarence Ahlem, Ann E. Huang
-
Patent number: 5055289Abstract: A complex of alpha-interferon with a monoclonal antibody complexes with the alpha-interferon without impairing its antiviral activity. The serum half-life of the interferon administered as the complex is substantially increased when compared to that of alpha-interferon administered alone.Type: GrantFiled: August 19, 1988Date of Patent: October 8, 1991Assignee: Hybritech IncorporatedInventors: James M. Frincke, Barbara W. Unger, Karen G. Burnett, Evan M. Hersh, Michael G. Rosenblum, Jordan U. Gutterman
-
Patent number: 5004606Abstract: A composition comprising a non-covalent immunocomplex of an anthracycline agent and an antibody selected to bind a target antigen and enhance the cytotoxicity of the anthracycline agent is disclosed. In accordance with the invention, the efficacy of an anthracycline as an anti-tumor agent for use in in vivo therapy is enhanced by administering to a patient a non-covalent immunocomplex provided herein.Type: GrantFiled: September 24, 1986Date of Patent: April 2, 1991Assignee: Hybritech IncorporatedInventors: James M. Frincke, Richard M. Bartholomew, Robert O. Dillman
-
Patent number: 4940718Abstract: 7-Substituted bicyclic pyrazolidinone compounds as antimicrobials and the corresponding intermediates, are discussed or provided. The use of the antimicrobial compounds in pharmaceutical compositions and in methods for treating bacterial infections is set forth.Type: GrantFiled: October 2, 1989Date of Patent: July 10, 1990Assignee: Eli Lilly and CompanyInventors: Charles J. Barnett, Richard E. Holmes, Louis N. Jungheim, Sandra K. Sigmund, Robert J. Ternansky
-
Patent number: 4902707Abstract: Bicyclic pyrazolidinones which have antimicrobial and/or herbicidal properties are discussed. The use of these compounds in pharmaceutical compositions, herbicidal compositions, and methods for treating bacterial infections and controlling undesired plants is set forth.Type: GrantFiled: April 30, 1985Date of Patent: February 20, 1990Assignee: Eli Lilly and CompanyInventors: Louis N. Jungheim, Sandra K. Sigmund
-
Patent number: 4892963Abstract: Compounds of the following formula have pharmaceutical properties: ##STR1## in which X is R.sup.1 (HO)C.dbd.C(CN)--, R.sup.1 (CO)--CH(CN)-- or ##STR2## R.sup.1 and R.sup.2 are each hydrogen or C.sub.1-6 alkyl, R.sup.3, R.sup.4 and R.sup.5 are each hydrogen, hydroxy, halogen, nitro, cyano, carboxy, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 alkylthio, halo-substituted C.sub.1-4 alkyl, halo-substituted C.sub.1-4 alkoxy, halo-substituted C.sub.1-4 alkylthio, C.sub.2-5 alkoxycarbonyl, optionally substituted phenyl, optionally substituted phenoxy, R'R"N- where R' and R" are each hydrogen or C.sub.1-4 alkyl R'"CONH-- where R'" is C.sub.1-4 alkyl, R.sup.6, R.sup.7 and R.sup.8 are each C.sub.1-6 alkyl, halo-substituted C.sub.1-6 alkyl or optionally substituted phenyl, or R.sup.6 and R.sup.7, together with the carbon atom to which they are attached, form a cycloalkyl group containing 3 to 7 carbon atoms, or R.sup.6, R.sup.7 and R.sup.Type: GrantFiled: August 7, 1987Date of Patent: January 9, 1990Assignee: Lilly Industries LimitedInventors: Peter T. Gallagher, Terence A. Hicks, Graham W. Mullier
-
Patent number: 4826992Abstract: 2,3-(Dihydro) bicyclic pyrazolidinones are intermediates for bicyclic pyrazolidinone antimicrobials.Type: GrantFiled: November 24, 1986Date of Patent: May 2, 1989Assignee: Eli Lilly and CompanyInventors: Louis N. Jungheim, Sandra K. Sigmund
-
Patent number: 4826993Abstract: 4-Substituted 1-(optionally substituted)diazolidinones are intermediates to 7-substituted bicyclic pyrazolidinone antimicrobials.Type: GrantFiled: May 14, 1986Date of Patent: May 2, 1989Assignee: Eli Lilly and CompanyInventors: Richard E. Holmes, Louis N. Jungheim
-
Patent number: 4795815Abstract: 1,2,4-Trisubstituted diazolidinones are intermediates to bicyclic pyrazolidinone antimicrobial compounds.Type: GrantFiled: October 29, 1987Date of Patent: January 3, 1989Assignee: Eli Lilly and CompanyInventor: Robert J. Ternansky
-
Patent number: 4767871Abstract: 4-(Protected amino)-3-oxo-1-(substituted and unsubstituted methylene)-1,2-pyrazolidinium ylides are intermediates to 7-substituted bicyclic pyrazolidione antimicrobials.Type: GrantFiled: April 30, 1987Date of Patent: August 30, 1988Assignee: Eli Lilly and CompanyInventors: Richard E. Holmes, Louis N. Jungheim
-
Patent number: 4748172Abstract: Cephalosporin compounds substituted in the 7-position by a 2-(5- or 6-membered heterocyclic)-2-oximinoacetylamino group and in the 3-position with an imidazolo, oxazolo or thiazolopyridinium-methyl group are broad spectrum antibiotics highly effective in combating bacterial infections of gram-negative and gram-positive microorganisms. The cephalosporins are best prepared by reacting a silylated 7-[2-(heterocyclic)-2-oximinoacetylamino-3-iodomethyl-3-cephem-4-carboxyli c acid with an imidazolopyridine, an oxazolopyridine or a thiazolopyridine. Pharmaceutical formulations comprising a compound of the invention and a method for treating bacterial infections comprising their use are also provided.Type: GrantFiled: January 12, 1987Date of Patent: May 31, 1988Assignee: Eli Lilly and CompanyInventor: Allen S. Katner
-
Patent number: 4734505Abstract: 1-(Alkylated)-2-(acylated)diazolidinones are intermediates to bicyclic pyrazolidinone antimicrobial compounds. The instant compounds have the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are as defined in the specification.Type: GrantFiled: May 14, 1986Date of Patent: March 29, 1988Assignee: Eli Lilly and CompanyInventor: Richard E. Holmes
-
Patent number: 4734504Abstract: 1-Alkylated diazolidinones are intermediates to bicyclic pyrazolidinone antimicrobial compounds. The instant compounds have the formula ##STR1## wherein R.sub.1, R.sub.2, and R.sub.3, have the meanings as defined in the specification.Type: GrantFiled: May 14, 1986Date of Patent: March 29, 1988Assignee: Eli Lilly and CompanyInventor: Richard E. Holmes